Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

Alzheimer’s Disease Treatment Special Notice

On September 27, 2022, the overall results of the large global phase 3 trial of lecanemab were released. This trial was carried out at sites throughout the Unites States and globally, in patients with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease). This drug is delivered intravenously and removes Alzheimer’s plaques from the brain. The results of this study are a landmark: it is the first drug proven to slow the course of Alzheimer’s disease. This drug, lecanemab, is now under consideration by the US Food and Drug Administration for approval, but is not yet approved or available commercially at this time.

Welcome

The Taub Institute for Research on Alzheimer's Disease and the Aging Brain is the nucleus of a dynamic, multidisciplinary endeavor.

The Institute brings together Columbia University researchers and clinicians to uncover the causes of Alzheimer's, Parkinson's and other age-related brain diseases and to discover ways to prevent and cure these diseases

Directors: Richard Mayeux, MD, MS, and
Michael Shelanski, MD, PhD
Deputy Directors: Philip De Jager, PhD, MD, MMSc and Rafael A. Lantigua, MD

The Taub Institute for Research on Alzheimer's Disease and the Aging Brain
Make an Appointment
Donate